GATA2 promotes glioma progression through EGFR/ERK/Elk-1 pathway

Among the gliomas, glioblastoma (GBM) is the highest grade and the most malignant glioma tumor. GATA2 is a hematopoietic factor that has been intensely studied in hematopoietic malignancies. Recently, the functions of GATA2 as an oncogene in other types of human cancer have been reported. However, no role for GATA2 in the development and progression of glioma has been reported to date. In the present study, we found that the expression level of GATA2 is upregulated in GBM and is correlated with GBM outcome. Ectopic expression of GATA2 or RNAi-mediated knockdown of GATA2 significantly enhanced or inhibited proliferation, migration and invasion of glioma cells. Moreover, we found that epidermal growth factor receptor and extracellular signal-regulated kinase, as upstream components of the signaling pathway, upregulate GATA2 expression; moreover, GATA2 promotes Elk-1 expression. Therefore, a genetic approach or pharmacological intervention targeting GATA2 could potentially serve as an effective strategy for treating glioma patients.

[1]  Zhixiang Wang,et al.  Differential Regulation of Transcription Factors by Location-Specific EGF Receptor Signaling via a Spatio-Temporal Interplay of ERK Activation , 2012, PloS one.

[2]  I. Kurnaz,et al.  Both mitogen-activated protein kinase (MAPK)/extracellular-signal-regulated kinases (ERK) 1/2 and phosphatidylinositide-3-OH kinase (PI3K)/Akt pathways regulate activation of E-twenty-six (ETS)-like transcription factor 1 (Elk-1) in U138 glioblastoma cells. , 2012, The international journal of biochemistry & cell biology.

[3]  Meifang Wang,et al.  Transient and sustained ERK phosphorylation and nuclear translocation in growth control , 2002, Journal of cellular physiology.

[4]  C. Rancourt,et al.  Ovarian cancer ascites increase Mcl-1 expression in tumor cells through ERK1/2-Elk-1 signaling to attenuate TRAIL-induced apoptosis , 2012, Molecular Cancer.

[5]  Kirby D. Johnson,et al.  Master regulatory GATA transcription factors: mechanistic principles and emerging links to hematologic malignancies , 2012, Nucleic acids research.

[6]  J. Crispino,et al.  Combinatorial regulation of tissue specification by GATA and FOG factors , 2012, Development.

[7]  Susan M. Chang,et al.  Medical therapy of gliomas , 2014, Journal of Neuro-Oncology.

[8]  C. Eng,et al.  GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. , 2012, Human molecular genetics.

[9]  Masayuki Yamamoto,et al.  A regulatory network governing Gata1 and Gata2 gene transcription orchestrates erythroid lineage differentiation , 2014, International Journal of Hematology.

[10]  M. Shigemori,et al.  CXCL12/CXCR4 signaling in malignant brain tumors: a potential pharmacological therapeutic target , 2011, Brain Tumor Pathology.

[11]  Julian Downward,et al.  The GATA2 Transcriptional Network Is Requisite for RAS Oncogene-Driven Non-Small Cell Lung Cancer , 2012, Cell.

[12]  M. Odero,et al.  The role of the GATA2 transcription factor in normal and malignant hematopoiesis. , 2012, Critical reviews in oncology/hematology.

[13]  T. Apanasovich,et al.  Glioma Grade Is Associated with the Accumulation and Activity of Cells Bearing M2 Monocyte Markers , 2013, Clinical Cancer Research.

[14]  Susan M. Chang,et al.  Glioblastoma Patients Epidermal Growth Factor Receptor , and Survival in Analysis of Complex Relationships between Age , p 53 , Updated , 2001 .

[15]  G. Blobel,et al.  GATA Transcription Factors and Cancer. , 2010, Genes & cancer.

[16]  J. Herman,et al.  Frequent hypermethylation of the DNA repair gene MGMT in long-term survivors of glioblastoma multiforme , 2007, Journal of Neuro-Oncology.

[17]  T. Merchant,et al.  Phase I and Pharmacokinetic Studies of Erlotinib Administered Concurrently with Radiotherapy for Children, Adolescents, and Young Adults with High-Grade Glioma , 2009, Clinical Cancer Research.

[18]  Ko-Jiunn Liu,et al.  Expression of cytoplasmic-domain substituted epidermal growth factor receptor inhibits tumorigenicity of EGFR-overexpressed human glioblastoma multiforme. , 2004, International journal of oncology.

[19]  C. Peschel,et al.  Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy , 2009, Clinical Cancer Research.

[20]  J. Xu,et al.  Curcumin inhibits human colon cancer cell growth by suppressing gene expression of epidermal growth factor receptor through reducing the activity of the transcription factor Egr-1 , 2006, Oncogene.

[21]  Ren Z.-P.,et al.  Planning for Intracavitary Anti-EGFR Radionuclide Therapy of Gliomas. Literature Review and Data on EGFR Expression , 2005, Journal of Neuro-Oncology.

[22]  C. Collins,et al.  GATA2 as a potential metastasis-driving gene in prostate cancer , 2014, Oncotarget.

[23]  Y. Marie,et al.  Combined analysis of TERT, EGFR, and IDH status defines distinct prognostic glioblastoma classes , 2014, Neurology.

[24]  Jill S. Barnholtz-Sloan,et al.  Epidemiologic and Molecular Prognostic Review of Glioblastoma , 2014, Cancer Epidemiology, Biomarkers & Prevention.

[25]  W. Cavenee,et al.  Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance. , 2012, Current cancer drug targets.

[26]  P. Black,et al.  Imaging of human mesenchymal stromal cells: homing to human brain tumors , 2012, Journal of Neuro-Oncology.